162 related articles for article (PubMed ID: 37637262)
1. Integrating Network Pharmacology and Experimental Validation to Explore the Effects and Mechanisms of Qinghao Biejia Decoction and Its Active Compound Artemisinin B Against Non-Small-Cell Lung Cancer.
Ye Y; Yang Y; Yan L; Zhou L; Yu S; Du Q; Dong X; Yuan Q; Shan L; Guo L
Drug Des Devel Ther; 2023; 17():2461-2479. PubMed ID: 37637262
[TBL] [Abstract][Full Text] [Related]
2. Green tea-derived theabrownin suppresses human non-small cell lung carcinoma in xenograft model through activation of not only p53 signaling but also MAPK/JNK signaling pathway.
Xiao X; Guo L; Dai W; Yan B; Zhang J; Yuan Q; Zhou L; Shan L; Efferth T
J Ethnopharmacol; 2022 Jun; 291():115167. PubMed ID: 35271947
[TBL] [Abstract][Full Text] [Related]
3. Investigating the efficacy and mechanisms of Jinfu'an decoction in treating non-small cell lung cancer using network pharmacology and in vitro and in vivo experiments.
Peng H; Huang Z; Li P; Sun Z; Hou X; Li Z; Sang R; Guo Z; Wu S; Cao Y
J Ethnopharmacol; 2024 Mar; 321():117518. PubMed ID: 38042385
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of n-butanol fraction of Wenxia Formula combining with gefitinib in treating non-small cell lung cancer based on network pharmacology and in vitro experiment].
Chen RJ; Bi QY; Shi JM; Zhong J; Han JT; Ji XM
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(2):471-486. PubMed ID: 38403323
[TBL] [Abstract][Full Text] [Related]
5. Qualitative and quantitative analysis of the major components in Qinghao Biejia decoction by UPLC-Orbitrap Fusion-MS/MS and UPLC-QQQ-MS/MS and evaluation of their antibacterial activities.
Cheng X; Li BP; Han ZX; Zhang FL; Jiang ZR; Yang JS; Luo QZ; Tang L
Phytochem Anal; 2022 Jul; 33(5):809-825. PubMed ID: 35546427
[TBL] [Abstract][Full Text] [Related]
6. Network Pharmacology-Based Exploration on the Intervention of Qinghao Biejia Decoction on the Inflammation-Carcinoma Transformation Process of Chronic Liver Disease via MAPK and PI3k/AKT Pathway.
Cheng X; Han ZX; Su ZJ; Zhang FL; Li BP; Jiang ZR; Tang L; Yang JS
Biomed Res Int; 2022; 2022():9202128. PubMed ID: 36277879
[TBL] [Abstract][Full Text] [Related]
7. Integrating network pharmacology and experimental verification to investigate the pharmacological mechanisms of Buzhong Yiqi decoction in the treatment of non-small cell lung cancer.
Zeng P; Wang F; Zhang J; Ur Rashid H; Li X; Zhang P; Luo Y; Wu X
Chem Biol Drug Des; 2024 Jan; 103(1):e14414. PubMed ID: 38230796
[TBL] [Abstract][Full Text] [Related]
8. Study on the material basis and action mechanisms of sophora davidii (Franch.) skeels flower extract in the treatment of non-small cell lung cancer.
Ye B; Chen P; Lin C; Zhang C; Li L
J Ethnopharmacol; 2023 Dec; 317():116815. PubMed ID: 37400006
[TBL] [Abstract][Full Text] [Related]
9. A network pharmacology approach and experimental validation to investigate the anticancer mechanism and potential active targets of ethanol extract of Wei-Tong-Xin against colorectal cancer through induction of apoptosis via PI3K/AKT signaling pathway.
Lin F; Zhang G; Yang X; Wang M; Wang R; Wan M; Wang J; Wu B; Yan T; Jia Y
J Ethnopharmacol; 2023 Mar; 303():115933. PubMed ID: 36403742
[TBL] [Abstract][Full Text] [Related]
10. Systems pharmacology unravels the synergic target space and therapeutic potential of Rhodiola rosea L. for non-small cell lung cancer.
Zhang X; Zhu J; Yan J; Xiao Y; Yang R; Huang R; Zhou J; Wang Z; Xiao W; Zheng C; Wang Y
Phytomedicine; 2020 Dec; 79():153326. PubMed ID: 32992083
[TBL] [Abstract][Full Text] [Related]
11. Disclosing targets and pharmacological mechanisms of total bioflavonoids extracted from Selaginella doederleinii against non-small cell lung cancer by combination of network pharmacology and proteomics.
Xu D; Wang X; Huang D; Chen B; Lin X; Liu A; Huang J
J Ethnopharmacol; 2022 Mar; 286():114836. PubMed ID: 34793885
[TBL] [Abstract][Full Text] [Related]
12. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
13. Synergy Mechanisms of Rhizoma Paridis Saponins on Non-small Cell Lung Cancer: Segmented Solid Phase Extraction, Bioactivity Screening, and Network Pharmacology.
Liu C; Ma Q; Du R; Chen M; Xing S; Yang Y; Rong R
Anticancer Agents Med Chem; 2022; 22(20):3466-3486. PubMed ID: 35652399
[TBL] [Abstract][Full Text] [Related]
14. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.
Wang Q; Wu H; Wu Q; Zhong S
Drug Dev Res; 2023 Aug; 84(5):907-921. PubMed ID: 37070571
[TBL] [Abstract][Full Text] [Related]
15. Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Yiqi Yangyin Decoction in Suppressing Non-Small-Cell Lung Cancer.
Jiao P; Wang Y; Ren G; Chu D; Li Y; Sang T
Biomed Res Int; 2023; 2023():4967544. PubMed ID: 36874921
[TBL] [Abstract][Full Text] [Related]
16. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
Jiang M; Zhou LY; Xu N; An Q
Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
[TBL] [Abstract][Full Text] [Related]
17. Integrated strategy of network pharmacology, molecular docking, HPLC-DAD and mice model for exploring active ingredients and pharmacological mechanisms of Penthorum chinense Pursh against alcoholic liver injury.
Jiang Y; Zhong M; Zhan H; Tao X; Zhang Y; Mao J; Geng Z; Gao B
J Ethnopharmacol; 2022 Nov; 298():115589. PubMed ID: 35926779
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
Min J; Shen H; Xi W; Wang Q; Yin L; Zhang Y; Yu Y; Yang Q; Wang ZN
Cell Physiol Biochem; 2018; 48(4):1433-1442. PubMed ID: 30064123
[TBL] [Abstract][Full Text] [Related]
19. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
20. Yi Qi Chu Tan Formula (YQCTF) inhibited the progress of lung cancer via regulating tumor-associated neutrophil: An integrated study of network pharmacology, proteomics and pharmacodynamics.
Le-Xin C; Ming-Jun L; Chun-Qi X; Jia-Xin Z; Jing-Ya Y; Li-Xin N; Mei-Qi W; En-Xin Z; Xiao-Jun Z
J Ethnopharmacol; 2024 Jan; 318(Pt B):116943. PubMed ID: 37532072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
